Punto Health has raised EUR 2.3 million in seed funding to accelerate rollout of its AI-powered, full-stack platform for dementia care, underlining continued investor appetite for clinically anchored healthtech addressing chronic conditions. The round was co-led by Shilling VC and Plus Partners, with participation from Exceptional Ventures, Heartfelt, Fondo Bolsa Social and ABAC Nest.
The company said the proceeds will be used to scale the product and support expansion in the UK and Spain. The funding was announced following a period of external validation for Punto Health, including winning the NN Social Innovation Award 2025 and selection for the AI-First Google Accelerator 2025.
A clear signal: investors are backing delivery models, not just software
This round fits a broader, with-trend pattern in European healthtech financing: capital is flowing to platforms that combine technology with a defined care pathway and evidence of clinical adoption. Punto Health positions itself as a “full-stack” dementia care platform, a framing that matters in a market where buyers and regulators increasingly demand measurable outcomes and operational integration.
Unlike many early-stage digital health products that struggle to move beyond pilots, Punto Health points to clinical validation with NHS trusts and the Ace Alzheimer Center. For investors, that traction reduces two of the hardest risks in dementia care innovation: proving clinical relevance and navigating institutional procurement.
From pre-seed to seed: stepping up the capital base
The EUR 2.3 million seed round also marks a progression in financing scale. Punto Health previously raised a pre-seed of around USD 840,000, and the larger seed cheque suggests a transition from concept and early validation to execution at scale.
The composition of the syndicate is notable. A co-lead structure with Shilling VC and Plus Partners and multiple additional backers indicates a willingness to underwrite the next stage of growth, even without broader market data on late-2025 European healthtech volumes. In mid-market terms, the message is straightforward: selective investors are still funding healthcare platforms that can demonstrate adoption, validation and a credible expansion plan.
Why dementia care attracts capital when evidence is credible
Dementia remains one of the most complex care categories to organise, spanning families, primary care, specialist services and long-term support. Platforms that streamline coordination, triage and ongoing support have a clear value proposition, but only if they can fit into real-world clinical workflows.
Punto Health’s emphasis on clinical validation and its focus on scaling across two healthcare systems suggests it is building for institutional buyers rather than consumer-only distribution. That matters because dementia care, by definition, involves carers and clinicians as core users, and not just the patient.
What to watch next
The strategic question for Punto Health now shifts from “does it work?” to “can it scale repeatably?” Investors will be looking for progress in three areas:
- Expansion execution: translating UK traction into Spain without diluting clinical quality or over-customising the product.
- Operational depth: maintaining a full-stack model without creating cost structures that outpace revenue growth.
- Clinical and commercial proof points: additional trust-level deployments and measurable outcomes that support broader procurement.
For the wider market, Punto Health’s seed round is a pragmatic indicator that well-evidenced, care-delivery healthtech remains financeable. The winners are the companies that pair AI claims with clinical validation and a clear plan to integrate into healthcare systems.